Navigation Links
Women Taking Oestrogen Therapy Showed Reduced Coronary Artery Calcification

The Research study found that younger menopausal women (aged 50-59) who received a standard dose of oral conjugated estrogens had significantly less coronary artery calcification at the end of the study period compared with those taking placebo. Coronary artery calcification is a marker of plaque in the arteries and a predictor of future cardiovascular events.

In the five years since the WHI study ended, new data have emerged that help put the initial findings into perspective. These results showed that in these younger menopausal women, estrogen therapy reduced calcified plaque buildup in the arteries, says Howard Hodis, M.D., Professor of Medicine and Preventive Medicine; Director, Artherosclerosis Research Unit, University of Southern California.

These data support initiation of estrogen therapy, where indicated when a woman first enters menopause and begins experiencing symptoms and bone loss.

Wyeth is unaware of any coronary artery calcification data for women taking estrogen plus progestin. The investigators did not study coronary artery calcification in women who were over 60 at the beginning of the study.

This study found no apparent increase in coronary heart disease for women who initiated hormone therapy within 10 years of menopause; and a statistically significant reduction in total mortality among women aged 50-59 in the group receiving hormone therapy compared with those in the placebo group.

The recent pooled analysis published in JAMA provides reassurance about coronary artery disease to newly menopausal women considering estrogen plus progestin therapy or estrogen alone therapy for symptom relief and prevention of postmenopausal bone loss.

The recent pooled analysis published in JAMA provides reassurance about coronary artery disease to newly menopausal women considering estrogen plus progestin therapy or estrogen alone therapy for symptom relief and prevention of postmenopausal bone loss.

The data published today in NEJM provide additional evidence for women considering estrogen alone therapy, says Joseph Camardo, M.D., Senior Vice President of Global Medical Affairs for Wyeth Pharmaceuticals. We hope this information can help clarify the clinical perspective for women who choose hormone treatment for menopausal symptoms and prevention of osteoporosis.

The authors conclude, Hormone therapy should not be initiated (or continued) for the express purpose of preventing cardiovascular disease in either younger or older postmenopausal women. The authors further state, The current recommendations from many organizations that hormone therapy be limited to the treatment of moderate to severe menopausal symptoms, with the lowest effective dose used for the shortest duration necessary, remain appropriate. Wyeth continues to support the use of hormone therapy.

Hormone therapy is not appropriate for all women. Women experiencing menopausal symptoms are encouraged to speak with their health care professional to determine whether hormone therapy might be the right treatment option for them.


'"/>




Related medicine news :

1. Women suffer from sexual dysfunction too
2. Women find difficulty in calling it Quits
3. Women recognise faces better
4. Women more susceptible to brain damage from ecstasy
5. Good News For Women With Gestational Diabetes
6. Unsatisfactory Grade On Womens Health Issues
7. Risk for Pregnant Women
8. Womens strong sense of smell
9. Women need to exercise more to prevent obesity
10. Women benefit from consuming fish
11. Women are at risk with raised cholesterol
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during the ... Life Science® and international water advocate, was honored by Ashram, Inc. as the world’s ... Egypt who knelt on the banks of the Nile to fill their red clay ...
(Date:5/26/2016)... ... May 26, 2016 , ... The introduction of our professional athletes ... YOUR HEAD ™”. , “We are proud to introduce Meghan Klingenberg, defender ... we have Brian Quick, wide receiver for Los Angeles who was a second round ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... Morrow-Fox . With over 20 years of experience in leading technology and human ... several years of university teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica ...
(Date:5/26/2016)... New York, NY (PRWEB) , ... May 26, 2016 , ... ... never have lips been so central to popular cosmetic improvement efforts. Record numbers of ... their kissers appear more prominent or pouty, says Kally Papantoniou, MD, of Advanced ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... is happy to announce the launch of its brand equity product, Brandvantage. ... to reflect the dynamic landscape of modern consumer decision-making. The proprietary framework ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 25,2016 FDA 510(k) clearance ... platform for urological and surgical applications ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) ... the US with the 12 th 510(k) ... (FDA). This new FDA clearance covers Confocal Miniprobes ...
(Date:5/25/2016)... May 25, 2016  According to Kalorama Information, the ... in 2015.  Though these are challenging times in ... for success for companies that remain optimistic and ... new growth prospects medical device companies spend a ... development (R&D) than do companies in other industries.  ...
(Date:5/25/2016)... -- MedDay, a biotechnology company focused on the ... entitled "High doses of biotin in progressive multiple sclerosis: extension ... Professor Ayman Tourbah , Principal Investigator of the Phase ... of Neurology (EAN) in Copenhagen, Denmark . ... place on Sunday, 29 May 2016 from 14:45 to 16:15 ...
Breaking Medicine Technology: